Osimertinib/osimertinib medical insurance reimbursement ratio in 2024

Osimertinib/Osimertinib is a targeted treatment for non-small cell lung cancer (NSCLC), specifically for patients with epidermal growth factor receptor (EGFR) mutations. It is a third-generation EGFR tyrosine kinase inhibitor. Compared with traditional first- and second-generation drugs, Osimertinib has higher selectivity and stronger inhibitory effect.

Osimertinib/The original drug of Osimertinib is currently on the market in China and has also been included in the medical insurance system. It belongs to Class B medical insurance and domestic patients can easily purchase it. Its domestic selling price remains in the range of three to four thousand yuan, but for specific prices and medical insurance reimbursement details, patients are advised to consult their local hospital pharmacy to obtain the most accurate information. In comparison, the prices of foreign generic drugs are more affordable, especially those listed in Laos and Bangladesh. Most of them cost only a few hundred yuan, which is significantly lower than the domestic price. It is worth mentioning that the ingredients of these generic drugs are basically the same as those of the original drugs.

Osimertinib/The biggest feature of Osimertinib is its high selectivity against EGFR T790M mutation. This mutation is one of the common mechanisms leading to drug resistance in NSCLC. In contrast, traditional EGFR inhibitors have limited effectiveness in the face of this mutation, while osimertinib/osimertinib can effectively inhibit this drug-resistant mutation, thus providing a new treatment option.

Clinical trials have shown that osimertinib/osimertinib has shown significant efficacy in the treatment of NSCLC patients with EGFR T790M mutations. Not only that, Osimertinib/Osimertinib also shows fewer toxic side effects, making it easier for patients to tolerate the treatment. This makesOsimertinib/Osimertinib has become one of the first-choice drugs for the treatment of advanced NSCLC.

In addition, osimertinib/osimertinib has also been shown to have a certain inhibitory effect on some other EGFR mutations , including sensitive mutations in the EGFR gene (such as Del19 and L858R). This makes osimertinib/osimertinib potentially therapeutic in patients with a variety of EGFRmutationsNSCLC.